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MaInactivation of platelet cyclooxygenase (COX)-1 by low-dose aspirin leads to long-lasting suppression of thromboxane
(TX) A2 production and TXA2-mediated platelet activation and aggregation. This effect is necessary and sufﬁcient to
explain aspirin’s unique (among other COX-1 inhibitors) effectiveness in preventing atherothrombosis, as well as its
shared (with other antiplatelet agents) bleeding liability. However, different mechanisms of action have been suggested
to explain other beneﬁcial effects of aspirin, such as prevention of venous thromboembolism, chemoprevention of
colorectal (and other) cancers, and reduced risk of dementia. These mechanisms include acetylation of other proteins in
blood coagulation, inhibition of COX-2 activity, and other COX-independent mechanisms. The intent of this review is to
develop the concept that the multifaceted therapeutic effects of low-dose aspirin may reﬂect pleiotropic consequences
of platelet inhibition on pathophysiological tissue repair processes. Furthermore, the clinical implications of this
concept will be discussed in terms of current clinical practice and future research. (J Am Coll Cardiol 2015;66:74–85)
© 2015 by the American College of Cardiology Foundation.M arketed in 1899 as a prototypic analgesic,antipyretic, and anti-inﬂammatory agent,aspirin continues to attract research and
debate related to its antiplatelet properties, which
were discovered and developed by the medical-
scientiﬁc community during the past 40 years (1).
The best-characterized molecular mechanism of the
action of aspirin as an antiplatelet drug is its perma-
nent inactivation of a critical platelet protein, pros-
taglandin G/H-synthase 1 (also colloquially referred
to as cyclooxygenase [COX]-1) (2). Inactivation of
COX-1 by low-dose aspirin leads to long-lasting sup-
pression of platelet thromboxane (TX) A2 production
and TXA2-mediated platelet activation and aggrega-
tion (3,4). This effect is necessary and sufﬁcient to
explain aspirin’s unique (among other COX-1 inhibi-
tors) effectiveness in preventing atherothrombosis
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beneﬁcial effects of aspirin, such as prevention of
venous thromboembolism (6), chemoprevention of
colorectal (and other) cancer (7), and reduced risk
of dementia (8). These mechanisms include acetyla-
tion of other proteins involved in blood coagu-
lation (6), inhibition of COX-2 activity (7), and other
COX-independent mechanisms (9).
The intent of this review is to develop the concept
that the apparently heterogeneous therapeutic ef-
fects of low-dose aspirin may reﬂect the pleiotropic
consequences of platelet COX-1 inhibition on patho-
physiological tissue repair processes that participate
in the healing response to vascular and mucosal
injury (Central Illustration). Furthermore, the clinical
implications of this concept will be discussed in terms
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AB BR E V I A T I O N S
AND ACRONYM S
ACS = acute coronary
syndrome(s)
ADP = adenosine diphosphate
COX = cyclooxygenase
GI = gastrointestinal
MI = myocardial infarction
NNH = number needed to harm
NNT = number needed to treat
NSAID = nonsteroidal
anti-inﬂammatory drug
PPI = proton pump inhibitor
TX = thromboxane
VTE = venous
thromboembolism
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75TREATMENT AND PREVENTION OF
ATHEROTHROMBOSIS
Platelets participate in the development and progres-
sion of atheromatous plaques and are key cellular
components of arterial occlusive thrombi (10). Adhe-
sion and aggregation of platelets in response to
ﬁssuring or rupture of an atheromatous plaque can be
viewed as a physiological repair response to an acute
vascular lesion. Appropriate control mechanisms of
thromboresistance (e.g., endothelial prostacyclin
production) normally limit the spatial extent and
duration of this platelet response. However, uncon-
trolled propagation and persistence of platelet activa-
tion through self-sustaining ampliﬁcation loops (e.g.,
TXA2/TP and adenosine diphosphate [ADP]/P2Y12 in-
teractions) may lead to intraluminal thrombus growth,
vascular occlusion, and transient ischemia or infarc-
tion (10). The ﬁndings that structurally unrelated in-
hibitors of prostacyclin production (different classes of
nonsteroidal anti-inﬂammatory drugs [NSAIDs]) in-
crease the risk of major atherothrombotic complica-
tions, particularly myocardial infarction (MI) (11),
whereas low-dose aspirin and P2Y12 blockers reduce
this risk (12), are consistent with these pathophysio-
logical concepts, and point to TXA2 and ADP as
important mediators of atherothrombosis (10). More-
over, the dynamic nature of this process explains the
effectiveness of low-dose aspirin in treating acute MI
and acute ischemic stroke (Figure 1), by interfering
with an important ampliﬁcation loop of thrombus
growth and new thrombus formation following phar-
macological or mechanical reperfusion (5,10). Finally,
the additive beneﬁcial effects of low-dose aspirin and
P2Y12 blockers in acute coronary syndromes (ACS) (12)
suggest nonredundant, complementary roles of TXA2
and ADP as ampliﬁers of platelet activation in coronary
atherothrombosis.
SECONDARY PREVENTION. Among patients with
occlusive vascular disease, both individual studies
(13) and meta-analyses of randomized trials of anti-
platelet therapy (14) indicate that low-dose aspirin
reduces the risk of a serious vascular event (nonfatal
MI, nonfatal stroke, or death from vascular causes) by
approximately one-fourth. Therefore, among a wide
range of patients with symptomatic vascular disease,
in whom the annual risk of a serious vascular event
ranges between 4% and 8%, low-dose aspirin may
prevent approximately 10 to 20 fatal and nonfatal
ischemic events for every 1,000 patients treated for 1
year (number needed to treat [NNT]: 50 to 100) (5)
(Figure 1). This substantial beneﬁt is obtained at the
expense of causing 1 to 2 major extracranial (mostlygastrointestinal [GI]) bleeding complications
per 1,000 patients (number needed to harm
[NNH]: 500 to 1,000) and 1 to 2 hemorrhagic
strokes per 10,000 patients (NNH: 5,000 to
10,000) (5). Therefore, for most high-risk pa-
tients taking low-dose aspirin, the number in
whom a serious vascular event would be
avoided clearly outweighs the number with a
major bleeding complication, unless an indi-
vidual patient has increased susceptibility to
bleeding due to advanced age, a history of GI
bleeding, or concomitant treatment with
NSAIDs or anticoagulant agents (5).
PRIMARY PREVENTION. Among asymptom-
atic subjects without a prior vascular event,
the balance of beneﬁts and risks of long-term
antiplatelet therapy with low-dose aspirin is
substantially uncertain because the risks without
aspirin, and hence the absolute beneﬁts of anti-
platelet prophylaxis, are at least an order of magni-
tude lower than in secondary prevention (15). On the
basis of a meta-analysis of individual participant
data from 6 primary prevention trials of aspirin in
approximately 90,000 subjects at average low vas-
cular risk, the Antithrombotic Trialists’ Collaboration
has shown that, irrespective of age or sex, the abso-
lute reduction in serious vascular events (largely,
nonfatal MI) would be only about twice as large as the
absolute increase in nonfatal GI bleeding (16). More-
over, the predicted 5-year absolute effects of alloca-
tion to aspirin in different categories of 5-year
coronary risk (from <5% to >10%) would yield a
relatively constant ratio between the calculated NNH
(from 1,000 to 100, respectively) and NNT values
(from 500 to 50, respectively) (16). This is not sur-
prising, inasmuch as the main risk factors for coro-
nary events were also associated with hemorrhagic
events, although for most the associations were
slightly weaker for bleeding than for ischemic events
(16). Thus, trying to identify a threshold risk level
above which recommending aspirin is expected to
produce substantially more beneﬁt than harm in
asymptomatic subjects (17) is probably a Sisyphean
exercise, as a patient at high ischemic risk because of
a cluster of cardiovascular risk factors is very unlikely
to be at low risk of bleeding. The current uncertainty
is reﬂected by conﬂicting guidelines on the use of
aspirin in primary prevention (Table 1) (17–20), as
well as by its heterogeneous regulatory status in
different countries (12). This may result in about 1 in
10 patients receiving inappropriate aspirin therapy
for primary prevention, with signiﬁcant practice-level
variations (21). Four ongoing primary prevention
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A wide repertoire of lipid and protein mediators, which may contribute to several clinical syndromes possibly responsive to low-dose aspirin therapy, are
released upon platelet activation and aggregation. The ﬁgure illustrates inhibition of platelet prostanoid production by aspirin and its functional and clinical
consequences. The lines of evidence supporting the protective effects of aspirin are summarized below each panel. AA ¼ arachidonic acid; ASPREE¼ ASPirin
in Reducing Events in the Elderly; RCT ¼ randomized controlled trial(s); PGE2 ¼ prostaglandin E2; PGH2 ¼ prostaglandin H2; TXA2 ¼ thromboxane A2.
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76trials may help assess the beneﬁt/risk proﬁle of
low-dose aspirin in preventing multiple outcomes
(including dementia and cancer) in approximately
50,000 participants at somewhat higher cardiovas-
cular risk than in the earlier trials, because of diabetes
mellitus (ASCEND [A Study of Cardiovascular Events
in Diabetes] and ACCEPT-D [Aspirin and Simvastatin
Combination for Cardiovascular Events Prevention
Trials in Diabetes]) (22,23), advanced age (ASPREE
[ASPirin in Reducing Events in the Elderly]) (24), or a
number of risk factors (ARRIVE [Aspirin to Reduce
Risk of Initial Vascular Events]) (25) (Table 2). In the
meantime, clinical judgment, as well as adequate
knowledge of the available data (Figure 2), may helpthe doctor–patient relationship to reach a personal-
ized therapeutic decision, after considering the
different components of a complex equation that
needs to incorporate the patient’s preferences and
values (15).
PREVENTION OF
VENOUS THROMBOEMBOLISM
Several lines of evidence support the hypothesis
that platelet activation in concert with neutrophil
recruitment is involved in the initiation and propa-
gation of deep vein thrombosis (6). The PEP (Pulmo-
nary Embolism Prevention) trial has clearly shown
FIGURE 1 Absolute Effects of Antiplatelet Therapy With Low-Dose Aspirin on the Risk
of Vascular Events (Nonfatal MI, Nonfatal Stroke, or Death From Vascular Causes)
in 5 Groups of High-Risk Patients
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The number needed to treat (NNT) ranged between 26 (acute myocardial infarction
[MI]) to 100 (acute stroke) per month of treatment in the acute setting, and from 65
(previous MI) to 105 (previous stroke) per year of treatment in the secondary prevention
setting. The ﬁgure is derived from an analysis of data from the Antithrombotic Trialists’
Collaboration (14). Reproduced with permission from Patrono et al. (5).
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77that short-term treatment with low-dose aspirin re-
duces the incidence of fatal pulmonary embolism and
symptomatic nonfatal deep vein thrombosis or pul-
monary embolism in patients with hip fracture (26).
The results of the PEP trial are consistent with the
meta-analysis performed by the Antiplatelet Trialists’
Collaboration (27), and supersede the ﬁndings in
most of the previous trials (13). Moreover, long-
term treatment with low-dose aspirin, after oral
anticoagulant agent discontinuation, has been shown
to reduce the risk of recurrence by more than one-
third in patients with a ﬁrst unprovoked venous
thromboembolism (VTE) (28). The postulated mech-
anisms underlying this protective effect of aspirin
against VTE include acetylation of ﬁbrinogen and
other proteins in blood coagulation, resulting in more
efﬁcient ﬁbrinolysis, and reduced thrombin genera-
tion at sites of vascular injury, possibly due to acet-
ylation of prothrombin (6). However, there is no
convincing evidence for ﬁbrinogen or prothrombin
acetylation being detectable in vivo after intake of
low-dose aspirin (6). Although aspirin can acetylate a
number of plasma proteins, enzymes, and DNA
in vitro (29), this usually requires millimolar con-
centrations that are approximately 100 to 1,000 times
higher than those achievable after oral dosing of low-
dose aspirin (30). Consistent with this requirement,
acetylation of serum albumin (31) and hemoglobin
(32) in vivo was reported following chronic oral
dosing with aspirin 3 to 6 g per day, that is, a 40-fold
to 60-fold higher dose than a typical antiplatelet
regimen. Therefore, the protective effect of low-dose
aspirin against VTE may well reﬂect an important role
of TXA2-mediated ampliﬁcation of platelet activation
and aggregation in VTE, rather than non–COX-
dependent mechanism(s) of action.
CHEMOPREVENTION OF
COLORECTAL CANCER
Several lines of evidence support a chemopreventive
effect of aspirin against some cancers, particularly of
the GI tract (7,9). These include: 1) a large number of
case-control and cohort studies that reported associ-
ations between aspirin use and reduced risk of colo-
rectal (and other) cancers (33); 2) 4 randomized,
placebo-controlled trials in subjects with sporadic
colorectal adenomas and their meta-analysis (34) that
demonstrated reduced risk of recurrence in aspirin-
treated subjects; 3) a placebo-controlled, random-
ized clinical trial in patients with Lynch syndrome
(hereditary nonpolyposis colon cancer), in whom
aspirin reduced cancer incidence during long-term
follow-up (35), but not during the scheduledtreatment phase of the trial (36); and 4) a post-hoc,
individual patient data meta-analysis of 51 random-
ized controlled trials of daily aspirin in prevention of
vascular events that reported a 25% reduction in
overall cancer incidence from 3 years onward (37).
None of these individual lines of evidence can un-
equivocally establish a cause-and-effect relationship
between exposure to aspirin and reduced risk of
colorectal (and other) cancers. However, they are
internally consistent and highly suggestive of a real
treatment effect after a variable latency. In particular,
the meta-analyses of cardiovascular trials (37–39) are
mechanistically interesting because they suggest that
the apparent chemopreventive effect of aspirin is
detectable at daily doses as low as 75 mg (38) and is
saturable at low doses; that is, much higher doses
(e.g., 1,200 mg daily) are not more effective than
lower doses (38). Moreover, reduced risk of devel-
oping colorectal cancer was also detected during
long-term follow-up of healthy women treated with
alternate-day 100 mg aspirin dosing versus placebo
(40), and of high-risk men treated with a 75-mg
controlled-release formulation of aspirin (38), devel-
oped to maximize cumulative inhibition of platelet
COX-1 in the pre-hepatic circulation and minimize
inhibition of COX-2 in the systemic vascular
TABLE 1 Guidelines on the Use of Aspirin in Primary Prevention
Organization
(Year) Recommendation
Class of
Recommendation
(Level of Evidence)
ESC WG on Thrombosis
(2014)
We recommend that aspirin use in the primary prevention of acute MI and other atherothrombotic
cardiovascular events in subjects of both sexes be guided by an assessment of the underlying
cardiovascular risk.
We suggest that aspirin be considered in the primary prevention of cardiovascular disease in both
sexes at a level of risk of major cardiovascular events (death, MI, and stroke) >2 per 100
subject-years, provided they have no clear evidence of increased risk of bleeding
(gastrointestinal bleeding or peptic ulcer disease, no concurrent use of other medications that
increase bleeding risk).
I (B)
IIa (B)
ESC
(2012)
Aspirin is not recommended in individuals without cardiovascular or cerebrovascular disease due to
the increased risk of major bleeding.
III (B)
ACCP
(2012)
We suggest low-dose aspirin (75–100 mg/day) in patients >50 years of age over no aspirin therapy. 2 (B)
USPSTF
(2009)
The USPSTF recommends the use of aspirin for men 45 to 79 years of age when the potential beneﬁt
due to a reduction in myocardial infarctions outweighs the potential harm due to an increase in
gastrointestinal hemorrhage.
The USPSTF recommends the use of aspirin for women 55 to 79 years of age when the potential
beneﬁt of a reduction in ischemic strokes outweighs the potential harm of an increase in
gastrointestinal hemorrhage.
A
A
ACCP ¼ American College of Chest Physicians; ESC ¼ European Society of Cardiology; MI ¼ myocardial infarction; USPSTF ¼ United States Preventive Services Task Force;
WG ¼ working group.
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78endothelium (41). Although several mechanisms of
action could explain a chemopreventive effect of
high-dose aspirin (9), including inhibition of COX-2
in the GI mucosa and its downstream effects on
cellular proliferation, apoptosis, and angiogenesis
(9), any effects of low-dose aspirin administered
once daily or every other day on nucleated cellular
targets would be more difﬁcult to reconcile with its
pharmacokinetics (very short half-life) and pharma-
codynamics (relatively selective inhibition of platelet
COX-1) (5,13). These considerations led us to suggest
that inhibition of platelet activation at sites of deep GI
mucosal lesions could be the primary mechanism of
action of low-dose aspirin, acting upstream of
platelet-driven COX-2 expression in adjacent nucle-
ated cells of the intestinal mucosa during the early
stages of colorectal carcinogenesis (42,43). DirectTABLE 2 Ongoing Randomized Trials of Low-Dose Aspirin for Primar
Study (Ref. #) Regimen(s)
Treatment
Duration N
ACCEPT-D
(23)
Aspirin 100 mg versus
open control; simvastatin
for all
5 yrs 5,17
ARRIVE (25) Aspirin 100 mg versus placebo 5 yrs w12,00
ASPREE (24) Aspirin 100 mg versus placebo 5 yrs w19,00
ASCEND (22) Aspirin 100 mg versus placebo
(u3FA vs. placebo)
7.5 yrs w15,00
ACCEPT-D ¼ Aspirin and Simvastatin Combination for Cardiovascular Events Preventi
ASCEND ¼ A Study of Cardiovascular Events in Diabetes; ASPREE ¼ ASPirin in Red
CVD ¼ cardiovascular disease; FA ¼ fatty acids; MI ¼ myocardial infarction; TIA ¼ transevidence of COX-2 induction in human colon cancer
cells by platelet-derived mediators has been reported
(44). Moreover, platelet activation and aggregation by
circulating cancer cells is hypothesized to protect
tumor cells from natural killer cell-mediated lysis
(45). Therefore, platelet inhibition may also help to
explain the apparent reduced risk of cancer metasta-
ses in cardiovascular trials of low-dose aspirin (46).
Finally, antiplatelet therapy with aspirin and clopi-
dogrel inhibits or delays immune-mediated hep-
atocarcinogenesis and improves survival in a mouse
model of chronic hepatitis B (47).
Additional evidence for the chemopreventive ef-
fects of aspirin is being sought prospectively in
ongoing primary prevention trials (Table 2). More-
over, several adjuvant trials of various low-dose
aspirin regimens have been initiated recently iny Prevention
Eligibility Primary Endpoint End Date
0 Diabetes,
no CVD
CV death, nonfatal stroke,
nonfatal MI, other CV
hospitalization
2015
0 10–20% estimated
10-yr risk of CHD
MI, stroke, CV death,
unstable angina, TIA
2016
0 Elderly, no diabetes
or CVD
Death, dementia or signiﬁcant
disability
2017
0 Diabetes, no CVD MI, stroke or TIA, or CV death 2018
on Trials in Diabetes; ARRIVE ¼ Aspirin to Reduce Risk of Initial Vascular Events;
ucing Events in the Elderly; CHD ¼ coronary heart disease; CV ¼ cardiovascular;
ient ischemic attack.
FIGURE 2 Beneﬁts and Risks of Low-Dose Aspirin in Primary Prevention Trials
Annual Risk of a Serious Vascular Event with Placebo (%)
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The numbers of vascular events avoided and episodes of major bleeding caused per 1,000
patients treated with aspirin per year are plotted from the results of individual placebo-
controlled trials of aspirin in different patient populations characterized by various degrees
of cardiovascular risk, as noted on the abscissa. Number needed to treat (NNT) and number
needed to harm (NNH) values are given for subjects in 3 categories of risk on the basis of
the presence or absence of randomized controlled trials. Modiﬁed with permission from
Patrono et al. (5). ACCEPT-D ¼ Aspirin and Simvastatin Combination for Cardiovascular
Events Prevention Trials in Diabetes; ASCEND ¼ A Study of Cardiovascular Events in
Diabetes; ARRIVE ¼ Aspirin to Reduce Risk of Initial Vascular Events; ASPREE ¼ ASPirin in
Reducing Events in the Elderly; BDT ¼ British Doctors Trial; HOT ¼ Hypertension Optimal
Treatment Study; PHS ¼ Physicians’ Health Study; PPP ¼ Primary Prevention Project;
SAPAT ¼ Swedish Angina Pectoris Aspirin Trial; TPT ¼ Thrombosis Prevention Trial;
WHS ¼ Women’s Health Study.
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79patients with newly diagnosed cancers, including
colorectal, gastroesophageal, breast, and prostate
cancer (Table 3).
PREVENTION OF VASCULAR DEMENTIA
Enhanced TXA2 biosynthesis in the chronic phase
after stroke is associated with the presence of post-
stroke dementia (48). Low-dose aspirin therapy has
been shown to reduce the risk of ischemic stroke
(5,13), and there is observational evidence of its po-
tential to reduce the rate of cognitive decline in the
elderly (8,24,49). It has recently been revealed that
platelets can behave as innate inﬂammatory cells in
immune responses with roles in leukocyte recruit-
ment (50), migration into tissues, release of cytotoxic
mediators, and in tissue remodeling following injury
(51). This proinﬂammatory platelet function involves
both complex formation with circulating leukocytes
and the secretion of soluble factors (Figure 3) (50,51).
Therefore, an anti-inﬂammatory effect of low-dose
aspirin that could contribute to reduced neuro-
degeneration does not necessarily require inhibition
of COX-2 in inﬂammatory cells, as would occur with
high daily doses of aspirin or other NSAIDs (52), but
may simply reﬂect its antiplatelet action. Moreover,
aspirin-triggered lipoxins (a family of eicosanoids
generated by interactions between 5-lipoxygenase
and aspirin-acetylated COX-2) have been suggested
to play a role in attenuating brain inﬂammation by
stimulating alternative activation of microglia (53).
However, although discovered 20 years ago (54), the
actual biosynthesis of these compounds in vivo re-
mains elusive.
The hypothesis that low-dose aspirin may pre-
vent or reduce the rate of cognitive decline in the
elderly has not been previously tested in a random-
ized clinical trial having dementia as the primary
endpoint. The ASPREE trial is a double-blind, ran-
domized, placebo-controlled primary prevention trial
with an average follow-up of 5 years, designed to
assess whether daily active treatment of oral 100 mg
enteric-coated aspirin will extend the duration of
disability-free and dementia-free life in healthy U.S.
participants 65 years of age and older for African
Americans and Hispanics and 70 years of age and
older for Caucasians and other minority groups (24).
OPTIMIZING LOW-DOSE ASPIRIN THERAPY
A sizeable proportion of patients with a clear indi-
cation to be treated with low-dose aspirin do not
receive the drug for a variety of reasons (55), or are
inadequately treated because of less than optimal
dose, dosing interval, or concomitant medications.The following is a list of practical issues that need to
be addressed in order to optimize antiplatelet therapy
with low-dose aspirin (Table 4).
1 . Are we using the optimal dose of aspirin? Though
current treatment guidelines recommend a range of
daily doses, the generally accepted aspirin dose is 75,
81, or 100 mg, depending on the available commercial
formulations of the drug in different countries.
Because even 75 mg is at least twice as high as the
lowest dose necessary and sufﬁcient to fully inhibit
platelet COX-1 activity upon repeated daily dosing (3),
there are no material differences in the antiplatelet
effects of doses ranging between 75 mg and 100 mg.
However, enteric coating may somewhat delay and
reduce aspirin absorption and impair its pharmaco-
dynamic effect in some subjects (56).
The “optimal” dose of aspirin was the subject of a
heated debate in the past, with several groups
advocating the requirement of somewhat higher
doses (e.g., 325 to 650 mg daily) in patients with ce-
rebrovascular disease or ACS (13). This issue has been
settled by randomized comparisons of higher versus
lower doses in patients with cerebrovascular disease
TABLE 3 Ongoing Randomized Trials of Aspirin Versus Placebo in High-Risk Cancer Patients
Study Regimen(s)
Treatment
Duration N Eligibility Primary Endpoint End Date
AspECT Aspirin 300 mg versus
placebo
8 yrs 2,500 Barrett’s esophagus Death/adenocarcinoma or
high-grade metaplasia
2017
seAFOod Aspirin 300 mg versus
placebo (EPA versus
placebo)
1 yr 904 Multiple adenomas at BCSP $1 adenoma at 1-yr screen NA
ASCOLT Aspirin 200 mg versus placebo 3 yrs 2,660 Dukes C or high-risk
Dukes B cancer
5-yr disease-free survival 2022
Add-Aspirin Aspirin 100 mg versus
aspirin 300 mg versus
placebo
5 yrs 9,920 CRC, breast, gastroesophageal,
prostate cancer
Disease-free survival (death
for gastroesophageal)
2025
ASCOLT ¼ Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers; AspECT ¼ Aspirin and Esomeprazole Chemoprevention Trial; BCSP ¼ bowel cancer screening program;
CRC ¼ colorectal cancer; EPA ¼ eicosapentaenoic acid; NA ¼ not available; seAFOod ¼ Systematic Evaluation of Aspirin and Fish Oil.
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80(57,58) and in ACS (59), showing no evidence of su-
periority of higher versus lower doses, and in fact
demonstrating that lower doses may be more effec-
tive than higher doses in the setting of carotid end-
arterectomy (58). The “aspirin wars” (60) are over,
and there is only one winner, that is, low-dose
aspirin. Using a 3-fold to 4-fold excess of the fully
effective dose would not be considered an accept-
able practice for any other drug treatment. Except for
a loading dose in the setting of ACS or acute ischemic
stroke, prescribing aspirin 325 mg daily for long-
term treatment would not produce any additional
beneﬁt, while exposing the patient to unnecessary
GI damage and undue bleeding complications, as
well as to potential negative interactions with
angiotensin-converting enzyme inhibitors (13) and
ticagrelor, a reversible P2Y12 blocker (61). It should
be noted that in both the TRITON-TIMI 38 (Trial
to Assess Improvement in Therapeutic Outcomes
by Optimizing Platelet Inhibition With Prasugrel-
Thrombolysis In Myocardial Infarction 38) (62) and
PLATO (Platelet Inhibition and Patient Outcomes)
(61) trials of improved P2Y12 blockade in ACS, there
was signiﬁcant geographical variation in aspirin
dosing, with North American patients receiving high-
dose aspirin more frequently than patients from
other places. Thus, in the PLATO trial, 54% of U.S.
patients took a median aspirin dose $300 mg/day
as compared to 2% in the rest of the world (63).
Interestingly, the lowest risk of cardiovascular death,
MI, or stroke with ticagrelor compared with clopi-
dogrel was associated with a low maintenance dose
of concomitant aspirin (63). Although the 2014
American Heart Association/American College of
Cardiology Non-ST Elevation-Acute Coronary Syn-
dromes guideline states that “the lower dose is
favored and all patients treated with ticagrelor
should receive only 81 mg per day,” as mandated bythe Food and Drug Administration, the summary of
recommendations table for antiplatelet therapy lists
the aspirin maintenance dose as 81 mg/day to 325 mg/
day (64). It is perhaps time for members of guideline
committees to come to terms with the available evi-
dence and stop recommending such a wide dose
range, in the interest of patients’ safety.
2 . Is a 24-h dosing interval suitable for all? Histori-
cally, the dosing interval for aspirin administration
has moved from 6 h (65) to up to 48 h (66,67), with
the appreciation that the duration of aspirin’s
antiplatelet effect was not dependent on the drug’s
half-life, but on the rate of platelet turnover (68).
However, the standard once-daily regimen may not
provide maximal platelet inhibition throughout the
24-h dosing interval in all patients. Incomplete in-
hibition of platelet COX-1 activity has been described
in association with obesity (69–71), diabetes mellitus
(70,72–74), essential thrombocythemia (75), and cor-
onary artery bypass surgery (76). In aspirin-treated
healthy subjects, negligible recovery of platelet
COX-1 activity is detectable for 24 to 48 h after low-
dose aspirin administration (3,77). This ﬁnding most
likely reﬂects COX-1 acetylation of bone marrow
megakaryocytes by aspirin (3,77,78). Reduced sys-
temic bioavailability of low-dose aspirin, as seen in
association with some enteric-coated formulations
(56,69), may be responsible for reduced acetylation
of platelet and megakaryocyte COX-1, resulting in
time-dependent recovery of platelet TXA2 produc-
tion during the 24-h dosing interval. Accelerated
platelet turnover, as characterized in a fraction
of the diabetic population (70) and in the vast
majority of patients with essential thrombocythemia
(79), may limit the duration of the antiplatelet effect
of low-dose aspirin and require twice-daily dosing
for sustained COX-1 suppression throughout the
dosing interval (70,79–81). A twice-daily regimen
FIGURE 3 Platelet-Derived Mediators of the Inﬂammatory Response
Activated platelets release inﬂammatory and mitogenic substances into the microenvironment, primarily altering the chemotactic, adhesive,
and proteolytic properties of the endothelium. Pre-formed platelet mediators, stored in a-granules, can be released immediately after platelet
activation through a process of exocytosis triggered by increased intracellular calcium levels. Activated platelets are also capable of time-
dependent synthesis of protein mediators, such as tissue factor and interleukin-1b. CD40 ligand is stored in the cytoplasm of resting platelets
and rapidly presents on the surface after platelet activation. After cleavage, to generate a soluble, functional fragment (soluble CD40 ligand),
the mediator is released into the extracellular environment, inducing inﬂammatory responses in the endothelium by binding CD40 on endo-
thelial cells. P-selectin is released from platelet granules and binds to the P-selectin glycoprotein ligand 1 (PSGL-1) receptor on monocytes,
enhancing the adhesion of the monocytes to vascular-cell adhesion molecule (VCAM) 1 and the other adhesins expressed on activated
endothelial cells and inducing the production of tissue factor by monocytes. Activated platelets also release chemokines that trigger the
recruitment of monocytes (e.g., regulated on activation normal T-cell expressed and secreted [RANTES]) or promote the differentiation of
monocytes into macrophages (e.g., platelet factor 4), as well as matrix-degrading enzymes such as matrix metalloproteinase (MMP) 2 or 9.
Interleukin-1b is a major mediator of platelet-induced activation of endothelial cells, causing enhanced chemokine release and up-regulation of
endothelial adhesion molecules to promote the adhesion of neutrophils and monocytes to the endothelium. H2O2 ¼ hydrogen peroxide; ICAM ¼
intracellular adhesion molecule; mRNA ¼ messenger RNA; MCP ¼ monocyte chemoattractant protein; O2– ¼ superoxide anion; OH– ¼ hydroxyl
radical. Reproduced with permission from Davì and Patrono (10).
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81of low-dose aspirin administration is currently con-
sidered in a personalized approach to antiplatelet
therapy in patients with myeloproliferative neo-
plasms (82).
3 . Do we need to worry about aspirin resistance? If
we deﬁne “resistance” in classical pharmacological
terms, that is, as the failure of aspirin intake to fully
inactivate platelet COX-1 (83), then aspirin resistance
is either a very rare phenomenon (56,77) or does not
exist. A relatively large study of 400 healthy vol-
unteers failed to identify a single case of true drug
resistance (56). “Pseudo-resistance,” reﬂecting de-
layed and reduced drug absorption, may complicateenteric-coated, but not immediate-release aspirin
administration (56). Noncompliance and/or drug-
drug interactions with some traditional NSAIDs, that
is, ibuprofen (84,85) and naproxen (86–88), are likely
to be responsible for many reports of aspirin “resis-
tance” in the published data, and should be carefully
considered in order to ensure persistent platelet in-
hibition by low-dose aspirin. Both noncompliance
and drug-drug interactions can be easily assessed by
serum TXB2 measurements performed before and
24 h after a witnessed aspirin intake (77). Increasing
the dose of aspirin will not improve platelet inhibi-
tion if the patient is not taking aspirin or is on
TABLE 4 Optimizing Low-Dose Aspirin Therapy
Suggested Action
Evidence
(Ref. #) Clinical Implication
1. Use the lowest effective dose (i.e., 75–100 mg daily) (13,57–59) Maximize clinical efﬁcacy; minimize gastrointestinal toxicity
and drug-drug interactions
2. Consider bid dosing in patients with type-2 diabetes
mellitus and essential thrombocythemia
(70,79–81) Ensure persistent inhibition of platelet function throughout
the dosing interval; clinical relevance remains untested
3a. Prefer non–enteric-coated formulations in obese patients
b. Improve compliance
c. Avoid concomitant administration of ibuprofen
and naproxen.
(54,69)
(77)
(84–88)
Improve extent and duration of platelet inhibition
Avoid misclassiﬁcation of “resistance”
Avoid interference with the antiplatelet effect of low-dose aspirin
4a. Avoid concomitant administration of gastrotoxic
medications (nonsteroidal anti-inﬂammatory drugs and
high-dose corticosteroids)
b. Consider proton pump inhibitors in high-risk patients
Consider eradication in H. pylori-positive patients
(93)
(89–91)
Improve gastrointestinal safety
Improve gastrointestinal safety
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82concomitant NSAID medication. However, improving
the patient’s motivation, stopping NSAID therapy (if
acceptable), or switching to an NSAID that does not
interfere with the antiplatelet action of aspirin (e.g.,
celecoxib or diclofenac) (84,85) will likely increase
the extent and duration of platelet inhibition by
a standard low-dose aspirin regimen. Similarly,
doubling the dose of aspirin administered once daily
does not prolong the duration of its antiplatelet effect
in diabetic or thrombocythemic patients with faster
recovery of platelet COX-1 during the 24-h dosing
interval (70,79), while increasing dosing frequency
(e.g., twice a day) results in persistent suppression of
COX-1 activity throughout the dosing interval (70,79).
4. Can we reduce asp i r in -assoc iated GI bleed ing
hazard? Both H2 receptor antagonists and proton
pump inhibitors (PPIs) reduce gastric acid secretion,
thus allowing gastric erosions and ulcers to heal (89).
Although PPIs have been shown effective in reducing
the risk of developing gastric and/or duodenal ulcers
associated with long-term use of low-dose aspirin in
elderly patients (90), no large randomized clinical
trials of PPI cotherapy have been completed using
upper GI bleeding as the primary endpoint. Although
it would be reasonable to expect that PPIs reduce
upper GI bleeding, they would not be effective in
reducing lower GI bleeding (91) and may actually in-
crease the risk of small bowel mucosal damage (92).
The HEAT (Helicobacter Eradication Aspirin Trial)
trial is currently testing the hypothesis that a 1-week
course of H. pylori eradication in 10,000 H. pylori-
positive patients using low-dose aspirin will halve
the incidence of subsequent peptic ulcer bleeding
that results in hospitalization. Avoidance of con-
comitant gastrotoxic medications (e.g., NSAIDs or
high-dose oral corticosteroids) may somewhat reduce
the risk of upper GI bleeding associated with low-
dose aspirin (93).CONCLUSIONS
The knowledge about low-dose aspirin as an anti-
platelet agent has evolved considerably over the past
30 years. Its beneﬁt/risk proﬁle in secondary preven-
tion is clearly favorable, and efforts should be made to
ensure that all patients with symptomatic cardiovas-
cular or cerebrovascular disease do take low-dose
aspirin regularly (55). However, the balance of poten-
tial beneﬁts and risks is substantially uncertain in
primary prevention, and efforts should be made to
avoid inappropriate over-prescription of low-dose
aspirin (21) until the results of ongoing trials become
available. In addition to rapidly becoming the corner-
stone of antithrombotic therapy, and maintaining
such a role in the face of newer antiplatelet agents,
low-dose aspirin has been instrumental in elucidating
the contribution of platelet-derived prostanoids to
atherothrombosis and VTE. The same investigative
approach is currently being used to dissect out the role
of platelet-derived lipid and protein mediators in in-
testinal carcinogenesis (43,52) and age-related cogni-
tive decline (24). If both the cardiovascular and
noncardiovascular effects of low-dose aspirin are due
to its antiplatelet properties, this raises the question as
to whether other antiplatelet drugs may share the
same spectrum of beneﬁcial effects discussed in this
review. The shorter duration of P2Y12 inhibitor trials
may limit the detectability of an anticancer effect, but
this remains to be explored in a meta-analysis of
these trials. Another interesting research question that
needs to be addressed in the appropriate experi-
mental setting is whether the ADP-P2Y12, TXA2-TP,
and thrombin-PAR-1 pathways of platelet activation
differentially modulate the release of speciﬁc pro-
inﬂammatory and proangiogenic mediators. The
translational axis leading to combined antiplatelet
therapy for cancer and/or dementia prevention would
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83then close the loop back to clinical investigation.
Finally, an appreciation that the most important clin-
ical effects of low-dose aspirin can be explained by
its unique antiplatelet properties is also useful in
clinical practice because it allows concentration on
those strategies that can realistically maximize its
efﬁcacy and minimize its bleeding complications.
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